



COMMISSIONER OF PATENTS AND THADEMARKS
Washington, D.C. 20231

Washington, D.O. 2025					18	
APPLICATION NO.	FILING DATE	FIRST NAMED IN	/ENTOR	A	TTORNEY DOCKET NO.	
09/114,844	07/14/9	B ASHKENAZI		Α	1129R1	
		HM12/0630	\neg	EXAMINER		
DIANE L. M	ARSCHANG,	·	KAUFMAN,C			
	SMITH, EDELL, WELTER, & SCHMIDT, P.A.				PAPER NUMBER	
90 SOUTH S	3100 NORWEST CENTER 90 SOUTH SEVENTH STREET			1646	11	
MINNEAPOLI	MINNEAPOLIS MN 55402-4131			DATE MAILED:	06/30/00	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks



UNITED STATES-DEPARTMENT OF COMMERCE Patent and Traden & Office

Address: ASSISTANT COIVINI SSIONER FOR PATENTS

Washington, D.C. 20231

APPLICATION NO./
CONTROL NO.

FILING DATE
FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER

Claire M. Kaufman

ART UNIT PAPER

1646

11

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Figures 1B and 1C show sequences for DR4, DR5 and DcR1, however, these sequences are not present in the CRF or paper copy of the Sequence Listing as required. Also, note that the Brief Description of the Drawings or the Drawings themselves must refer to the SEQ ID NO of all sequences in a drawing.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Claire Kaufman whose telephone number is (703) 305-5791. The examiner can normally be reached on Mon-Thurs.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler can be reached on (703) 308-6564. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Claire M. Kaufman Patent Examiner

There 28, 2000

. " . I	, *	Application No.	Applicant(s)						
•	Notice to Comply	09/114,844	ASHKENAZI ET AL.						
	Notice to Comply	Examiner	Art Unit						
		Claire M. Kaufman	1646						
	NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES								
	oplicant must file the items indicated below within the ti oid abandonment under 35 U.S.C. § 133 (extensions o								
	ne nucleotide and/or amino acid sequence disclosure c r such a disclosure as set forth in 37 C.F.R. 1.821 - 1.8		not comply with t	he requirements					
	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).								
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).								
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).								
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."								
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).								
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).								
\boxtimes	7. Other: <u>su attached</u>								
	pplicant Must Provide: An initial or <u>substitute</u> computer readable form (CRF)) copy of the "Sequence Listing".							
	An initial or <u>substitute</u> paper copy of the "Sequence Lecification.	_isting", as well as an amendmen	t directing its entr	y into the					
	A statement that the content of the paper and comp new matter, as required by 37 C.F.R. 1.821(e) or 1.82			plicable, include					
Fo	or questions regarding compliance to these re	equirements, please contact							

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212

Patentin Software Program Support